🟢 Krystal Biotech is trading 5% up today ahead of Q2 earnings and rebounding from recent losses

Krystal Biotech is trading at $358.00 (5% up) in pre-market, rebounding from a 7% drop in the previous session as investors position ahead of the company's Q2 earnings report.

• Krystal Biotech is scheduled to report Q2 2026 results on August 03, with consensus estimates calling for $122.61 million in revenue and $1.70 EPS.
• The move highlights expectations for continued commercial strength, supported by an average analyst price target of $376.75.